Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by National Bank of Canada FI

National Bank of Canada FI boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 196.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 190,912 shares of the medical equipment provider’s stock after buying an additional 126,528 shares during the quarter. National Bank of Canada FI owned approximately 0.08% of Hologic worth $15,551,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Innealta Capital LLC acquired a new stake in shares of Hologic during the 2nd quarter valued at about $25,000. Wolff Wiese Magana LLC acquired a new stake in Hologic in the third quarter valued at approximately $25,000. Sunbelt Securities Inc. purchased a new stake in shares of Hologic in the second quarter valued at approximately $37,000. First Horizon Advisors Inc. raised its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Finally, Cromwell Holdings LLC lifted its position in shares of Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.75% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. UBS Group boosted their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday. Royal Bank of Canada upped their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Leerink Partners lowered their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $89.50.

Hologic Stock Up 1.4 %

NASDAQ:HOLX opened at $76.83 on Wednesday. Hologic, Inc. has a 52 week low of $68.15 and a 52 week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The stock’s fifty day moving average is $79.62 and its two-hundred day moving average is $78.60. The stock has a market capitalization of $17.44 billion, a price-to-earnings ratio of 23.07, a price-to-earnings-growth ratio of 2.37 and a beta of 0.96.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period last year, the business posted $0.89 EPS. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.